POINT MARCHÉS L'Europe clôture dans le rouge, Wall Street hésite à mi-séance

European shares dip ahead of ECB policy decision

Viatris forecasts strong 2024 sales on higher demand for branded drugs

European shares flat on rate-hike jitters; Novo Nordisk jumps

AstraZeneca to Buy CinCor Pharma for Up to $1.8 Billion

Idorsia submits a new drug application to the FDA

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Insiders own 33% of Idorsia Ltd (VTX:IDIA) shares but individual investors control 39% of the company

Insiders own 33% of Idorsia Ltd (VTX:IDIA) shares but individual investors control 39% of the company

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany